Overview
Nimustine has been used in trials studying the treatment of Glioblastoma.
Indication
适用于脑瘤、肺癌、慢性白血病、恶性淋巴瘤、消化道癌。
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2016/03/03 | Phase 2 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
No FDA approvals found for this drug. |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
Nimustine Hydrochloride for Injection | 国药准字H20059251 | 化学药品 | 注射剂 | 7/18/2024 | |
Nimustine Hydrochloride for Injection | 国药准字H20046672 | 化学药品 | 注射剂 | 6/19/2020 | |
Nimustine Hydrochloride for Injection | 国药准字H20058694 | 化学药品 | 注射剂 | 3/3/2022 | |
Nimustine Hydrochloride for Injection | 国药准字H20046533 | 化学药品 | 注射剂 | 7/28/2020 | |
Nimustine Hydrochloride for Injection | 国药准字H20065314 | 化学药品 | 注射剂(冻干粉针剂) | 1/28/2021 | |
Nimustine Hydrochloride for Injection | 国药准字H20059604 | 化学药品 | 注射剂 | 9/16/2023 | |
Nimustine Hydrochloride for Injection | 国药准字H20057157 | 化学药品 | 注射剂 | 7/13/2022 | |
Nimustine Hydrochloride for Injection | 国药准字H20053686 | 化学药品 | 注射剂 | 8/6/2024 | |
Nimustine Hydrochloride for Injection | 国药准字H20044292 | 化学药品 | 注射剂 | 5/22/2020 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
No TGA approvals found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.